JPRN-UMIN000011179已完成2 期
Phase II study of 3-weeks cycle of S-1 as first-line for advanced pancreatic cancer (PACS-3) - 3-weeks cycle of S-1 for pancreatic cancer (PACS-3)
Gifu University Hospital0 个研究点目标入组 70 人开始时间: 2013年7月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Pulmonary fibrosis or interstitial pneumonia. 2) Watery diarrhoea. 3) Active infections, excluding viral hepatitis. 4) Serious complications (e.g. heart failure, renal failure, hepatic failure, haemorrhagic peptic ulcer, intestinal paralysis, intestinal obstruction or poorly controlled diabetes). 5) Moderate or severe ascites or pleural effusion requiring treatment. 6) Metastasis in the CNS. 7) Active double cancer. 8) Patients under treatment with flucytosine, phenytoin or warfarin potassium. 9) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 10) Severe mental disorder. 11) Judged ineligible by physicians for participation in the study from a safety viewpoint.
研究者
相似试验
已完成
2 期
A phase II study of S-1 (14days-administrarion followed by 7days-rest ) for Metastatic Breast CancerBreast CancerJPRN-UMIN000014096Tokyo Women's Medical University25
未知
2 期
Phase II Study of S-1 plus LV (1 week on and 1 week off) as First-line Treatment for Patients with metastatic colorectal cancer.Colorectal CancerJPRN-jRCT2080220727Taiho Pharmaceutical Co., Ltd.
已完成
2 期
Multicenter phase II study of S-1 plus Weekly Cisplatin in first-line treatment of unresectable or reccurent gastric cancergastric cancerJPRN-UMIN000001858Tsukuba Cancer Clinical Trial Group70
已完成
2 期
A Multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancerJPRN-UMIN000007386Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine28
已完成
不适用
Phase II study of S-1 for relapsed or refractory thymoma or thymic carcinomaThymoma/Thymic carcinomaJPRN-UMIN000008174orth Japan Lung Cancer Group40